Loading
A phase 2 trial of adebrelimab and nALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) in pancreatic cancer, run by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, not yet recruiting.
Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer is a phase 2, interventional study registered as NCT07827053 by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, with a registry enrolment figure of 36 participants, started 2026-09-01 and due to reach its primary completion in 2029-09-01. Interventions recorded: Adebrelimab (PD-L1 inhibitor); NALIRIFOX; SBRT. Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC). Primary outcome: surgical conversion rate. Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed pancreatic ductal adenocarcinoma". No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Adebrelimab, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV), Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag pancreatic-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag pancreatic-deep-dive.
Shares NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV), Locally advanced unresectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Adebrelimab, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Adebrelimab, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, SBRT / SABR (stereotactic radiotherapy), Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Adebrelimab, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/